Radiotherapy Utilization in Traditional Medicare and Medicare Advantage
In this cross-sectional study, MA patients with cancer undergoing radiotherapy had higher estimated spending and greater mean treatment length than those covered by TM. Despite lower utilization of more expensive advanced treatment modalities, MA was not associated with cost savings. Whether MA meets the value proposition for radiation oncology requires further investigation.
Authors
- Tianfeng Zhang (ORCID: https://orcid.org/0000-0003-3632-4982)
- E. John Orav
- Jacob Hogan (ORCID: https://orcid.org/0000-0001-5235-671X)
- Miranda B. Lam (ORCID: https://orcid.org/0000-0001-7885-6317)
- Alexander Spektor (ORCID: https://orcid.org/0000-0002-1085-3205)
- Thomas C. Tsai (ORCID: https://orcid.org/0000-0002-9183-016X)
- Jie Zheng (ORCID: https://orcid.org/0000-0002-4035-8520)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Harvard Affiliated Emergency Medicine Residency (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.3018
- Citations
- 3
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Harvard University
- Harvard Catalyst
- Arnold Ventures
- National Institutes of Health
- National Cancer Institute
- National Center for Advancing Translational Sciences